

## UCI Medical Center Clinical Trials Web Page Standard Research Recruitment Advertisement Format

Note: This form must be submitted to the IRB for approval either as part of a new protocol application or with a request for modification to an IRB-approved protocol (electronic Protocol Modification (e-mod) Request can be found at [www.rgs.uci.edu/hs/mod](http://www.rgs.uci.edu/hs/mod)). When you have received approval from the IRB for the advertisement text, please provide a stamped copy to Leanne Spaide, UCI Medical Center, Marketing and Public Relations Department, Rt. 163A, fax (714) 456-8968, for posting on the [www.ucihealth.com](http://www.ucihealth.com) clinical trials Web page.

1. Lead Researcher: Kenneth Linden, M.D., Ph.D.

2. Study Title: A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients - RegiSONIC

3. Purpose of Study (e.g., to evaluate a new drug for breast cancer): The purpose of this research study is to collect information about the treatments that patients with advanced type of basal cell skin cancer (aBCC) or basal cell carcinoma nevus syndrome (BCCNS) receive, including how well they work and how safe they are.

4. Eligibility (e.g., adults on medication for high blood pressure; diabetic patients on insulin; normal, healthy adults; etc.): Adults who have been diagnosed with aBCC or BCCNS.

5. Location (if other than UCIMC):

Dermatology Clinical Research Center, University of California, Irvine, 1001 Hewitt Hall, Irvine CA 92697

Gottschalk Medical Plaza, 2100 Medical Plaza Drive, Irvine, CA 92697

Chao Family Comprehensive Cancer Center, 101 The City Drive, Orange CA 92686

6. Time Commitment (e.g., three one-hour long visits in three weeks): This study includes approximately 21 visits and takes about *8 hours* over a period of *approximately 5 years*. This study will help researchers learn more about aBCC and BCCNS, and it is hoped that this information will help in the treatment of future patients with these conditions in the future.

7. Anticipated Benefits (if any): You will not directly benefit from participation in this study. This study is not designed to treat any illness or to improve your health. This study will help researchers learn more about aBCC and BCCNS, and it is hoped that this information will help in the treatment of future patients with these conditions in the future.

8. Compensation (if any): none

9. Contact Name, UCI Department, Phone Number and E-mail:

---

HS# 2012-9136

Approved by IRB on: 02/25/13

IRB USE ONLY - DO NOT ALTER THIS FOOTER



Brian Swasdibutra  
UCI Department of Dermatology  
949-824-7103  
bswasdib@uci.edu

Signature of Lead Researcher: \_\_\_\_\_ Date: \_\_\_\_\_

IRB Approval Granted on:

